Executive Summary
AbCellera Biologics has established itself as a global leader in AI-driven antibody discovery, combining advanced computational biology, high-throughput wet-lab systems, and deep immunology expertise to rapidly identify therapeutic antibodies. Best known for its pivotal role in discovering COVID-19 antibodies with Eli Lilly, AbCellera has since expanded into a diversified, partner-rich platform supporting antibody programs across oncology, immunology, metabolic disease, and rare disorders.
By 2025, AbCellera’s expanding collaboration portfolio and growing internal pipeline reflect a strategic shift from pandemic-era responsiveness toward long-term, platform-driven value creation in biologics discovery.
AI as the Operating System for Antibody Discovery
AbCellera’s technology platform integrates machine learning, single-cell analysis, and high-throughput antibody screening to analyze millions of immune cells and rapidly identify high-quality antibody candidates.
The platform enables:
- Rapid interrogation of natural immune repertoires
- AI-driven prediction of antibody developability and function
- Accelerated progression from discovery to IND-ready candidates
This approach positions AbCellera as both a discovery partner and a biologics innovation engine, addressing pharma’s need for speed, scale, and biological relevance.
Landmark Partnership with Eli Lilly Established Platform Credibility
AbCellera gained global prominence through its collaboration with Eli Lilly to discover neutralizing antibodies against SARS-CoV-2. The partnership resulted in authorized COVID-19 antibody therapies and generated hundreds of millions of dollars in revenue for AbCellera during the pandemic.
Beyond financial impact, the Lilly collaboration validated AbCellera’s platform at unprecedented speed and scale, establishing the company as a trusted partner for rapid-response and high-confidence antibody discovery.
Expanding Biopharma Collaborations Drive Long-Term Value
Following its COVID-19 success, AbCellera broadened its partnership base to include multiple global pharmaceutical companies:
- Eli Lilly (Expanded Discovery Collaboration)
Beyond COVID-19, AbCellera and Lilly expanded their relationship to include antibody discovery programs across oncology, immunology, and other therapeutic areas, with milestone and royalty economics supporting long-term value generation. - Regeneron Collaboration
AbCellera partnered with Regeneron to apply its antibody discovery platform to selected therapeutic targets, combining AbCellera’s AI-enabled discovery with Regeneron’s development and commercialization capabilities. - Bristol Myers Squibb Collaboration
A multi-program agreement with Bristol Myers Squibb focuses on discovery of novel antibodies, with AbCellera eligible for research payments, development milestones, and royalties. - Pfizer and Additional Global Pharma Partners
AbCellera has disclosed multiple discovery partnerships with large pharmaceutical companies, many undisclosed by name, collectively representing multi-billion-dollar potential milestone value across dozens of antibody programs.
Across its portfolio, AbCellera has initiated more than 100 discovery programs, with over 50 programs advancing into preclinical and clinical development, underscoring the scalability of its platform.
Strategic Shift Toward Internal Pipeline Ownership
In parallel with partnerships, AbCellera has increasingly invested in internal antibody programs, retaining greater downstream value. Internal candidates span oncology, immunology, and metabolic disease, with several assets progressing through IND-enabling studies and early clinical development.
This hybrid strategy—partnered discovery plus selective asset ownership—positions AbCellera to balance near-term collaboration revenue with long-term pipeline upside.
Capital Strength and Platform Investment
AbCellera remains well capitalized following its public listing and pandemic-era revenues. Capital allocation priorities include:
- Continued expansion of AI and computational biology capabilities
- Scaling of wet-lab automation and single-cell analysis systems
- Advancement of internal antibody programs toward clinical proof-of-concept
The company’s disciplined capital strategy reflects a focus on platform durability rather than single-asset risk.
Positioning in the AI Biologics Landscape
While many AI drug discovery companies focus on small molecules, AbCellera occupies a differentiated position at the intersection of AI, immunology, and biologics. Compared with peers such as Recursion, Insilico Medicine, or Exscientia, AbCellera’s competitive advantage lies in its direct access to human immune intelligence combined with machine learning and industrial-scale biology.
As antibody therapeutics continue to dominate biologics pipelines, this positioning aligns closely with pharma’s long-term R&D priorities.
Outlook
By 2025, AbCellera Biologics stands as one of the most established and commercially validated AI-enabled discovery platforms in biopharma. With a deepening network of pharmaceutical partners, a growing internal pipeline, and a proven ability to translate AI insights into approved therapies, AbCellera is positioned to generate sustained value well beyond its pandemic legacy.
As the industry increasingly prioritizes speed, biological relevance, and scalable discovery, AbCellera’s AI-powered antibody engine is emerging as a cornerstone of next-generation biologics innovation.
By